Does HPV-18 co-infection increase the risk of cervical pathology in individuals with HPV-16?

Autor: Gökkaya M; Department of Gynecological Oncology, Antalya Training and Research Hospital, Health Science University, Antalya, Turkey., Alcı A; Department of Gynecological Oncology, Antalya Training and Research Hospital, Health Science University, Antalya, Turkey., Aytekin O; Department of Gynecological Oncology, Ankara Bilkent City Hospital, Health Science University, Ankara, Turkey., Unsal M; Department of Gynecological Oncology, Ankara Bilkent City Hospital, Health Science University, Ankara, Turkey., Cakır C; Department of Gynecological Oncology, Etlik Zubeyde Hanim, Women's Health and Research Hospital, Health Science University, Ankara, Turkey., Oktar O; Department of Gynecological Oncology, Etlik Zubeyde Hanim, Women's Health and Research Hospital, Health Science University, Ankara, Turkey., Yalcin N; Department of Gynecological Oncology, Antalya Training and Research Hospital, Health Science University, Antalya, Turkey., Kahraman A; Department of Gynecological Oncology, Antalya Training and Research Hospital, Health Science University, Antalya, Turkey., Tokalioglu A; Department of Gynecological Oncology, Ankara Bilkent City Hospital, Health Science University, Ankara, Turkey., Ersak B; Department of Gynecological Oncology, Ankara Bilkent City Hospital, Health Science University, Ankara, Turkey., Yıldırım HEK; Department of Gynecological Oncology, Etlik Zubeyde Hanim, Women's Health and Research Hospital, Health Science University, Ankara, Turkey., Koc S; Department of Gynecological Oncology, Etlik Zubeyde Hanim, Women's Health and Research Hospital, Health Science University, Ankara, Turkey., Toptas T; Department of Gynecological Oncology, Antalya Training and Research Hospital, Health Science University, Antalya, Turkey., Kilic F; Department of Gynecological Oncology, Ankara Bilkent City Hospital, Health Science University, Ankara, Turkey., Celik F; Department of Gynecological Oncology, Ankara Bilkent City Hospital, Health Science University, Ankara, Turkey., Boran N; Department of Gynecological Oncology, Etlik Zubeyde Hanim, Women's Health and Research Hospital, Health Science University, Ankara, Turkey., Ustun Y; Department of Gynecological Oncology, Etlik Zubeyde Hanim, Women's Health and Research Hospital, Health Science University, Ankara, Turkey., Tekin OM; Department of Gynecological Oncology, Ankara Bilkent City Hospital, Health Science University, Ankara, Turkey., Comert GK; Department of Gynecological Oncology, Ankara Bilkent City Hospital, Health Science University, Ankara, Turkey., Korkmaz V; Department of Gynecological Oncology, Etlik Zubeyde Hanim, Women's Health and Research Hospital, Health Science University, Ankara, Turkey., Turan T; Department of Gynecological Oncology, Ankara Bilkent City Hospital, Health Science University, Ankara, Turkey., Ureyen I; Department of Gynecological Oncology, Antalya Training and Research Hospital, Health Science University, Antalya, Turkey.
Jazyk: angličtina
Zdroj: Cytopathology : official journal of the British Society for Clinical Cytology [Cytopathology] 2024 Jul 11. Date of Electronic Publication: 2024 Jul 11.
DOI: 10.1111/cyt.13422
Abstrakt: Objective: We aimed to investigate differences between HPV-16 mono- and HPV-16/18 co-infections in terms of cervical dysplasia and invasive cancer.
Methods: This multicentre, retrospective study spanned from December 2017 to December 2020, involving women who visited gynaecological oncology clinics for colposcopy with either HPV-16 or HPV-16/18 positivity. A total of 736 patients, 670 in Group 1 (HPV-16 positivity) and 66 in Group 2 (HPV-16/18 positivity), were compared for the presence of CIN2+ lesions detected by colposcopic biopsy or endocervical curettage (ECC). Exclusions included hysterectomized patients, those with prior gynaecological cancers, and patients with HPV positivity other than types 16 and 18.
Results: Among the included patients, 42.4% had a diagnosis of CIN2+ lesions. The cytology results demonstrated abnormal findings in 45.3% in Group 1 and 42.2% in Group 2, with no significant difference between the groups. ECC revealed CIN2+ lesion in 49 (8.7%) patients in group 1, while only 1 (1.7%) patient had CIN2+ lesion in group 2. There was no difference between 2 groups in terms of ECC result (p = 0.052). In group 1, 289 (43.1%) patients had CIN2+ lesion, while 23 (34.8%) patients had CIN2+ lesions in group 2. There was no difference between group 1 and 2 in terms of diagnosis of CIN2+ lesions (p = 0.19).
Conclusion: This multicentre retrospective study found no significant differences between HPV-16 mono- and HPV-16/18 co-infections regarding cervical pathologies. Larger studies are needed to validate and further explore these findings.
(© 2024 John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: